Although there are indications that ecstasy users have higher levels of depression, impulsivity, and sensation seeking, it is unknown whether these are consequences of ecstasy use or predisposing factors for starting ecstasy use. We prospectively assessed the predictive value of depression, impulsivity, and sensation seeking on future .rst time ecstasy use. We also assessed whether depression, impulsivity, and sensation seeking had changed after .rst ecstasy use. Depression, impulsivity, and sensation seeking were assessed using self-report questionnaires in 188 ecstasynaive volunteers with high probability for future ecstasy use. After a mean follow-up of 17 months, measurements were repeated in 59 incident ecstasy users (mean 6.0 tablets) and 61 matched persistent ecstasy-naive volunteers. Only experience seeking (subscale of the sensation seeking scale) predicted future ecstasy use (OR -- 1.05, 95% CI 1.00 to 1.10), but after adjustment for potential confounders this was not signi.cant anymore. At follow-up, signi.cant effects of ecstasy use on the general and the disinhibition subscale of the sensation seeking scale were observed (after adjustment for potential confounders: regression coef.cient B 0.51, 95% CI 0.20 to 0.83 and B -- 3.25, 95% CI 1.74 to 4.76, respectively). These data indicate that depression, impulsivity, and sensation seeking do not predict .rst time ecstasy use in a population of young adults with the intention to start using ecstasy and that low level ecstasy use does not seem to cause depression or impulsivity. However, low level ecstasy use may increase (certain aspects of) sensation seeking.
Abraham M D, Kaal H L, Cohen P D A (2002) Licit and illicit drug uses in the Netherlands. Cedro/Mets & Schilt, Amsterdam
2.
Bardo M T, Donohew R L, Harrington N G (1996) Psychobiology of novelty seeking and drug seeking behavior. Behavioural Brain Research77: 23–43
3.
Beck A T, Steer R A (1984) Internal consistencies of the original and revised Beck Depression Inventory. J Clin Psychol40: 1365–1367
4.
Beck A T, Ward C H, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry4: 561–571
5.
Bender E (2005) FDA approves study of ecstasy in some terminally ill patients. Psychiatric News40: 46–46
6.
Bolla K I, McCann U D, Ricaurte G A (1998) Memory impairment in abstinent MDMA (‘Ecstasy’) users. Neurology51: 1532–1537
7.
Bond A J, Verheyden S L, Wingrove J, Curran H V (2004) Angry cognitive bias, trait aggression and impulsivity in substance users. Psychopharmacology171: 331–339
8.
Bouman T K, Luteijn F, Albersnagel F A, Van der Ploeg F A E (1985) Enige ervaringen met de Beck Depression Inventory (BDI). Gedrag13: 13–24
9.
Butler G K, Montgomery A M (2004) Impulsivity, risk taking and recreational ‘ecstasy’ (MDMA) use. Drug Alcohol Depend76: 55–62
10.
Check E (2004) Psychedelic drugs: the ups and downs of ecstasy. Nature429: 126–128
11.
Cohen Z, Bonvento G, Lacombe P, Hamel E (1996) Serotonin in the regulation of brain microcirculation. Prog Neurobiol50: 335–362
12.
Curran H V (2000) Is MDMA (‘Ecstasy’) neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology42: 34–41
13.
Daumann J, Pelz S, Becker S, Tuchtenhagen F, Gouzoulis-Mayfrank E (2001) Psychological profile of abstinent recreational Ecstasy (MDMA) users and significance of concomitant cannabis use. Human Psychopharmacology – Clinical and Experimental16: 627–633
14.
Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E (2004) Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacology173: 398–404
15.
De Win M M L, Reneman L, Reitsma J B, den Heeten G J, Booij J, van den Brink W (2004) Mood disorders and serotonin transporter density in ecstasy users – the influence of long-term abstention, dose, and gender. Psychopharmacology (Berl)173: 376–382
16.
De Win M M L, Jager G, Vervaeke H, Schilt T, Reneman L, Booij J, Verhulst F C, den Heeten G J, Ramsey N F, Korf D J, van den Brink W (2005) The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance. Int J Methods in Psychiatric Research, in press
Drugs Informatie en Monitoring Systeem (2003b) Jaarbericht 2003. DIMS/Trimbos-instituut, Utrecht
19.
Drugs Informatie en Monitoring Systeem (2004) Jaarbericht 2004. DIMS/Trimbos-instituut, Utrecht
20.
Dughiero G, Schifano F, Forza G (2001) Personality dimensions and psychopathological profiles of ecstasy users. Hum Psychopharmacol16: 635–639
21.
Feij J A, van Zuilen R W (1984) Handleiding bij de spanningsbehoeftelijst (SBL). Swets & Zeitlinger, Lisse
22.
Feij J A, van Zuilen R W, Gazendam A (1982) De ontwikkeling van een Nederlandse vragenlijst voor sensation seeking: de spanningsbehoeftelijst (SBL). Gedrag10: 364–383
23.
Fossati A, Di Ceglie A, Acquarini E, Barratt E S (2001) Psychometric properties of an Italian version of the Barratt Impulsiveness Scale-11 (BIS-11) in nonclinical subjects. Journal of Clinical Psychology57: 815–828
24.
Gamma A, Buck A, Berthold T, Vollenweider F X (2001) No difference in brain activation during cognitive performance between ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: a [H215O]-positron emission tomography study. J Clin Psychopharmacol21: 66–71
25.
Gamma A, Frei E, Lehmann D, Pascual-Marqui R D, Hell D, Vollenweider-F X (2000) Mood state and brain electric activity in ecstasy users. Neuroreport11: 157–162
26.
Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R, Caccavari R, Delsignore R (1998) Serotonergic function after (±)3,4-methylenedioxymethamphetamine (‘ecstasy’) in humans. Int Clin Psychopharmacol13: 1–9
27.
Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E, Marzocchi G F, Delsignore R, Brambilla F (2000) Long-lasting effects of (±)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biological Psychiatry47: 127–136
28.
Gerra G, Angioni L, Zaimovic A, Moi G, Bussandri M, Bertacca S, Santoro G, Gardini S, Caccavari R, Nicoli M A (2004) Substance use among high-school students: relationships with temperament, personality traits, and parental care perception. Substance Use and Misuse39: 345–367
29.
Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert H J, Fimm B, Sass H (2000) Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry68: 719–725
30.
Halpern J H, Pope H G Jr, Sherwood A R, Barry S, Hudson J I, Yurgelun-Todd D (2004) Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend75: 135–147
31.
Hosmer D W, Lemeshow S (2001) Applied Logistic Regression. Textbook and Solutions Manual. Wiley, New York
32.
Kruesi M J P, Rapoport J L, Hamburger S, Hibbs E, Potter W Z, Lenane M, Brown G L (1990) Cerebrospinal-fluid monoamine metabolites, aggression, and impulsivity in disruptive behavior disorders of children and adolescents. Archives of General Psychiatry47: 419–426
33.
Laviola G, Adriani W, Terranova M L, Gerra G (2000) Psychobiologic risk factors and vulnerability to psychostimulants in adolescents and animal models. Ann Ist Super Sanita36: 47–62
34.
Lieb R, Schuetz C G, Pfister H, von Sydow K, Wittchen H U (2002) Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug and Alcohol Dependence68: 195–207
35.
Lucki I (1998) The spectrum of behaviors influenced by serotonin. Biological Psychiatry44: 151–162
36.
McCann U D, Eligulashvili V, Ricaurte G A (2000) (±)3,4-Methylenedioxymethamphetamine (‘ecstasy’)-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology42: 11–16
37.
McCown W G (1988) Multi-impulsive personality disorder and multiple substance abuse: evidence from members of self-help groups. Br J Addict83: 431–432
38.
MacInnes N, Handley S L, Harding G F A (2001) Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. Journal of Psychopharmacology15: 181–186
39.
Malison R T, Price L H, Berman R, van Dyck C H, Pelton G H, Carpenter L, Sanacora G, Owens M J, Nemeroff C B, Rajeevan N, Baldwin R M, Seibyl J P, Innis R B, Charney D S (1998) Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 βcarbomethoxy-3 β-(4-iodophenyl)tropane and single photon emission computed tomography. Biological Psychiatry44: 1090–1098
40.
Marlowe M J (1993) Biological aspects of personality disorder. Br J Hosp Med49: 564–569
41.
Meneses A (1999) 5-HT system and cognition. Neuroscience and Biobehavioral Reviews23: 1111–1125
42.
Morgan M J (1998) Recreational use of ‘ecstasy’ (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology19: 252–264
43.
Morgan M J (2000) Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl)152: 230–248
44.
Morgan M J, McFie L, Fleetwood H, Robinson J A (2002) Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?Psychopharmacology (Berl)159: 294–303
45.
Nelson H E (1991) The Revised National Adult Reading Test Manual. NFER-Nelson, Windsor
46.
Netter P, Hennig J, Roed I S (1996) Serotonin and dopamine as mediators of sensation seeking behavior. Neuropsychobiology34: 155–165
47.
Paine T A, Dringenberg H C, Olmstead M C (2003) Effects of chronic cocaine on impulsivity: relation to cortical serotonin mechanisms. Behavioural Brain Research147: 135–147
48.
Parrott A C (2001) Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol16: 557–577
49.
Parrott A C, Sisk E, Turner J J D (2000) Psychobiological problems in heavy ‘ecstasy’ (MDMA) polydrug users. Drug and Alcohol Dependence60: 105–110
50.
Parrott A C, Milani R M, Parmar R, Turner J J D (2001) Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology159: 77–82
51.
Parrott A C, Buchanan T, Scholey A B, Heffernan T, Ling J, Rodgers J (2002) Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Human Psychopharmacology – Clinical and Experimental17: 309–312
52.
Patton J H, Stanford M S, Barratt E S (1995) Factor structure of the Barratt Impulsiveness Scale. Journal of Clinical Psychology51: 768–774
53.
Pedersen W (1991) Mental health, sensation seeking and drug use patterns: a longitudinal study. British Journal of Addiction86: 195–204
54.
Pedersen W, Skrondal A (1999) Ecstasy and new patterns of drug use: a normal population study. Addiction94: 1695–1706
55.
Reneman L, Lavalaye J, Schmand B, de Wolff F A, van den Brink W, den Heeten G J, Booij J (2001a) Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’): preliminary findings. Arch Gen Psychiatry58: 901–906
56.
Reneman L, Booij J, de Bruin K, Reitsma J B, de Wolff F A, Gunning W B, den Heeten G J, van den Brink W (2001b) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet358: 1864–1869
57.
Reneman L, de Win M M L, Jager G, Ramsey N F, van den Brink W, Booij J, den Heeten G J (2006) Neuroimaging findings with MDMA/Ecstasy: technical aspects, conceptual issues and future prospects. J of Psychopharmacology20: 163–174
58.
Ricaurte G A, Yuan J, McCann U D (2000) (±)3,4-Methylenedioxymethamphetamine (‘ecstasy’)-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology42: 5–10
59.
Roiser J P, Rogers R D, Sahakian B J (2005a) Neuropsychological function in ecstasy users: a study controlling for polydrug use. Psychopharmacology (Berl)1–12 (online)
60.
Roiser J P, Cook L J, Cooper J D, Rubinsztein D C, Sahakian B J (2005b) Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users. Am J Psychiatry162: 609–612
61.
Schifano F (2000) Potential human neurotoxicity of MDMA (‘ecstasy’): subjective self-reports, evidence from an Italian Drug Addiction Centre and clinical case studies. Neuropsychobiology42: 25–33
62.
Schmand B, Bakker D, Saan R, Louman J (1991) The Dutch Reading Test for Adults: a measure of premorbid intelligence level. Tijdschr Gerontol Geriatr22: 15–19
63.
Schuster P, Lieb R, Lamertz C, Wittchen H U (1998) Is the use of ecstasy and hallucinogens increasing? Results from a community study. European Addiction Research4: 75–82
64.
Sumnall H R, Cole J C (2005) Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis. J Psychopharmacol19: 84–92
65.
Taylor J R, Jentsch J D (2001) Repeated intermittent administration of psychomotor stimulant drugs alters the acquisition of Pavlovian approach behavior in rats: differential effects of cocaine, d-amphetamine and 3,4-methylenedioxymethamphetamine (‘ecstasy’). Biological Psychiatry50: 137–143
66.
The Netherlands National Drug Monitor. Annual Report 2003. Trimbos Institute, Utrecht
67.
Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A (2003) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology (Berl)167: 85–96
68.
Topp L, Barker B, Degenhardt L (2004) The external validity of results derived from ecstasy users recruited using purposive sampling strategies. Drug Alcohol Depend73: 33–40
69.
Tuchtenhagen F, Daumann J, Norra C, Gobbelé R, Becker S, Pelz S, Sass H, Buchner H, Gouzoulis-Mayfrank E (2000) High intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users. Neuropsychopharmacology22: 608–617
70.
Van de Wijngaart G, Braam R, de Bruin D, Fris M, Maalsté N, Verbraeck H (1997) Ecstasy in het uitgaanscircuit (Ecstasy and the Dutch rave scene: a socio-epidemiologic study on the nature and extent of, and the risks involved in using ecstasy and other party drugs at dance events). Addiction Research Institute, Utrecht
71.
Virkkunen M, Rawlings R, Tokola R, Poland R E, Guidotti A, Nemeroff C, Bissette G, Kalogeras K, Karonen S L, Linnoila M (1994) CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch Gen Psychiatry51: 20–27
72.
Welch G, Hall A, Walkey F (1990) The replicable dimensions of the Beck Depression Inventory. J Clin Psychol46: 817–827
73.
Witt E D (1994) Mechanisms of alcohol abuse and alcoholism in adolescents: a case for developing animal models. Behav Neural Biol62: 168–177
74.
Zimmermann P, Wittchen H U, Waszak F, Nocon A, Höfler M, Lieb R (2005) Pathways into ecstasy use: the role of prior cannabis use and ecstasy availability. Drug Alcohol Depend79: 331–341
75.
Zuckerman M (1994) Behavioral expressions and biosocial bases of sensation seeking. Cambridge University Press, Cambridge, MA
76.
Zuckerman M, Link K (1968) Construct validity for the sensation-seeking scale. J Consult Clin Psychol32: 420–426
